http://www.i-base.info/htb/index.html Not-for-profit technical review of latest treatment research and news relating to clinical management of HIV. 7 thu, 17 jul 2008 14:15:00 GMT thu, 17 jul 2008 14:15:00 GMT   en-gb HIV i-Base and contibutors rss@i-base.org.uk rss@i-base.org.uk   http://www.i-base.info/htb/v9/htb9-7-8/17th.html Despite the fall in the value of the dollar, European delegates are fortunate that this specialist resistance workshop still alternates between European and North American sites. This years meeting in Sitges included a healthy balance between basic science and studies with more direct clinical importance.     http://www.i-base.info/htb/v9/htb9-7-8/Integrase.html Several research groups presented results on generally small groups of highly treatment experienced patients who are no longer responding to raltegravir-based regimens.   http://www.i-base.info/htb/v9/htb9-7-8/Understanding.html Although etravirine (ETV) was approved in the US in January 2008, [1] the indication to not rely on ETV with only two new RTIs, and its interaction profile with other ARVs, have limited it’s use, other than with darunavir as in the DUET registrational studies. http://www.i-base.info/htb/v9/htb9-7-8/Lack.html Frank Maldarelli from the US HIV Drug Resistance Programme, and colleagues, presented results from a small treatment intensification study looking to clarify the source of residual viraemia in patients with viral load suppressed to ‹50 copies/mL.   http://www.i-base.info/htb/v9/htb9-7-8/14th.html The annual BHIVA spring conference held this year in Dublin, has two main aims. In addition to presenting overview lectures on important aspects of HIV care and management - often given by international experts, it aims to encourage UK-based research and case studies by presenting research from junior doctors and researchers.     http://www.i-base.info/htb/v9/htb9-7-8/Bone.html M Rosenvinge and colleagues from St Georges reported an unexpectedly high rate of vitamin D deficiency in a retrospective case note review of 132 consecutive patients attending their out-patients clinic from November 2007.   http://www.i-base.info/htb/v9/htb9-7-8/15th.html The last three issues of HTB included reports on antiretrovirals and treatment strategies, prevention of mother-to-child transmission (PMTCT), paediatrics, hepatitis coinfection, opportunistic infections and treatment access from this important conference.   http://www.i-base.info/htb/v9/htb9-7-8/Boosted.html On 24th June 2008, the European Commission granted marketing authorisation for atazanavir boosted by ritonavir (300mg/100mg once daily), in combination with other antiretrovirals, as a first-line treatment HIV-1 infected adults.   http://www.i-base.info/htb/v9/htb9-7-8/UK.html The 2008 BHIVA guidelines are now published online and are a significant revision of the 2006/7 guidelines.   http://www.i-base.info/htb/v9/htb9-7-8/Major.html Two important new long-awaited guidelines relating to the management and treatment of opportunistic infections were published online in June. http://www.i-base.info/htb/v9/htb9-7-8/Free.html Since 2001, the British School of Osteopathy (BSO) has been running a free Friday morning treatment programme called the Chapman Clinic for HIV positive patients from its premises on Borough High Street, south east London.